We, therefore, tested whether the combination of vvDD/vvDD-IL-2-RG and anti-PD-1/PD-L1 or anti-CTLA-4 antibody could improve the therapeutic effects using the late-stage tumour model. Here, CTLA4 is linked to neoplasm.